A Review of OIE Country Status Recovery Using Vaccinate-to-Live Versus Vaccinate-to-Die Foot-and-Mouth Disease Response Policies I: Benefits of Higher Potency Vaccines and Associated NSP DIVA Test Systems in Post-Outbreak Surveillance
Authors:
- 24 September 2013
- journal article
- review article
- Published by Hindawi Limited in Transboundary and Emerging Diseases
- Vol. 62 (4) , 367-387
Abstract
To rapidly return to trade, countries with OIE status, FMD-free country where vaccination is not practised, have destroyed emergency vaccinated animals, raising ethical concerns with respect to social values, the environment, animal welfare and global food security. This two-part review explores whether science could support eligibility to return to previous OIE status in 3 months irrespective of vaccinate-to-live or vaccinate-to-die policies. Here, we examine the benefits of higher potency (≥ 6 PD50 ), high-purity vaccines formulated from antigen banks for emergency use, their efficacy and performance in differentiating infected from vaccinated animals (DIVA) assays for post-outbreak surveillance. From an intensive programme of research, we conclude that high-quality, higher potency vaccines are proven to reduce FMD virus (FMDV) subclinical circulation and the risk of carriers. Broader coverage than predicted by serology suggests the potential to hold a few 'key' vaccine strains improving logistics and reducing the financial burden of antigen banks. The OIE should adopt formal definitions for emergency vaccination and emergency vaccines. In terms of supportive tools, we consider that the lack of OIE recognition of DIVA tests other than those of PANAFTOSA in cattle is a shortcoming. There is need for research on maternal antibody interference with DIVA tests and on the use of such tests to establish whether greater purification of vaccines improves performance. We consider that alignment of waiting periods for vaccinate-to-live and vaccinate-to-die in OIE Code Article 8.5.9 1 b. and c. is feasible until an acceptable level of statistical certainty for surveillance or target probability of freedom is established to substantiate the absence of FMDV infection or circulation. It is surveillance intensity rather than waiting periods that establishes the risk of residual FMDV. EU Directive 2003/85/EC implicitly recognizes this, permitting derogation of the OIE waiting periods.Keywords
This publication has 74 references indexed in Scilit:
- High potency vaccines induce protection against heterologous challenge with foot-and-mouth disease virusVaccine, 2008
- Modelling studies to estimate the prevalence of foot-and-mouth disease carriers after reactive vaccinationProceedings Of The Royal Society B-Biological Sciences, 2007
- Comparative evaluation of six ELISAs for the detection of antibodies to the non-structural proteins of foot-and-mouth disease virusVaccine, 2006
- Non-capsid proteins to identify foot-and-mouth disease viral circulation in cattle irrespective of vaccinationBiologicals, 2005
- Comparison of Two 3ABC Enzyme-Linked Immunosorbent Assays for Diagnosis of Multiple-Serotype Foot-and-Mouth Disease in a Cattle Population in an Area of EndemicityJournal of Clinical Microbiology, 2004
- Evidence that high potency foot-and-mouth disease vaccine inhibits local virus replication and prevents the ‘carrier’ state in sheepVaccine, 2004
- Aspects of emergency vaccination against foot-and-mouth diseaseComparative Immunology, Microbiology and Infectious Diseases, 2002
- A review of emergency foot-and-mouth disease (FMD) vaccinesVaccine, 2002
- Improvement of a serodiagnostic strategy for foot-and-mouth disease virus surveillance in cattle under systematic vaccination: a combined system of an indirect ELISA-3ABC with an enzyme-linked immunoelectrotransfer blot assayArchives of Virology, 2000
- The Role of Small Ruminants in the Epidemiology and Transmission of Foot-and-Mouth DiseaseThe Veterinary Journal, 1999